Abstract 1558P
Background
The Keystone-001 study was designed to prospectively evaluate the efficacy and safety of preoperative treatment with pembrolizumab plus paclitaxel and cisplatin followed by Da Vinci robotic radical surgery in patients with locally advanced (stage III) ESCC. The study also explored the potential mechanism of this treatment strategy (NCT 04389177, 5/15/2020).
Methods
The full study methods for this prospective, single-arm, single-center, open-label, phase-II study have been published previously. For further investigating the immune cell subpopulations that determine the efficacy, we performed single-cell sequencing on peripheral blood and tumor tissues after neoadjuvant therapy, and validated using flow cytometry.
Results
Of the 49 patients enrolled between July 8, 2020, and February 10, 2022, 47 received neoadjuvant therapy and were included in the ITT analysis. Among all patients who received neoadjuvant therapy, no grade ≥3 AEs were reported. Improvements from baseline nutritional status were observed with increases in patients’ median body weight and NRI. QoL evaluations showed improvements from baseline to post-adjuvant therapy in all functional scales and symptom scales of EORTC QLQ-C30 and in all items of the EORTC QLQ-OES18 questionnaire. Among all 45 patients in the efficacy analysis, the MPR rate was 73.3%, the pCR rate was 42.2%, the ORR was 95.6%, and the DCR was 100%. After a median follow-up of 23.3 months (95% CI 20.6, 24.9; maximum follow-up 34 months), the 1- and 2-year OS and DFS rates were 95.6 and 90.5% and 95.6 and 86.3%, respectively. The single-cell sequencing results showed that the main cell populations that affect the response of this treatment strategy were NKT and NK cell subpopulations in peripheral blood. Further analysis results showed that the TRGC2+NKT and FGFBP2+NK cell subpopulation in peripheral blood were more significantly increased in peripheral blood from patients with a good response.
Conclusions
The preliminary findings of this trial were safe and effective, and further phase III studies (Keystone-002) have begun to recruit participants.
Clinical trial identification
NCT 04389177.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tianjin Science and Technology Bureau, Beijing Xisike Clinical Oncology Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1489P - To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer
Presenter: Ye Mao
Session: Poster session 21
1490P - Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Presenter: Mustafa Bozkurt
Session: Poster session 21
1491P - PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
Presenter: Jeongmin Seo
Session: Poster session 21
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1495P - Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Presenter: Ana Baramidze
Session: Poster session 21
1496P - Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Paul Takam Kamga
Session: Poster session 21
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21